ÂÜÀòÂÒÂ×

Since joining CI in 2006, Kevin has led investments in Convexity Scientific, Torigen Pharmaceuticals, Affinimark Technologies, Cara Therapeutics (IPO), CaroGen Corporation, Discover Video, HistoRx (sold to Genoptix), Intelligent Clearing Network, Oil Purification Systems, Oxford Performance Materials, Perosphere, Precipio Diagnostics (IPO), Rapid Oxygen and Solais Lighting (sold to PowerSecure), Mininvasive Orthopedics Solutions, OmniCyte and others. He was on the board of Standing Stone when it was sold to Alere.

Kevin is a founding member and on the board of the UConn Innovation Fund, a partnership with Webster Bank, UConn and CI that makes investments in UConn-related technologies.

He managed CI’s $46 million BioFacilities Fund, which invested in wet laboratory space for bioscience companies, and managed CI’s two incubator laboratories in Science Park in New Haven. Kevin was also involved in the establishment of the Connecticut Stem Cell Fund and managed CI’s PreSeed program, which makes investment in very early-stage companies with small convertible-debt instruments.

Before joining CI, Kevin was director of the Office of Bioscience at the Connecticut Department of Economic and Community Development (DECD), where he led the organization’s efforts in bioscience business recruitment, client interaction, bioscience-related public policy strategy and day-to-day operations. While at DECD, Kevin also served as director of business recruitment in DECD’s Business Recruitment and Industry Clusters Division, negotiating relocation incentive packages for high-priority corporate development projects, including UBS in Stamford, Pfizer’s clinical facility in New Haven and DST Output’s facility in South Windsor.